Trial Profile

A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 16 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Duvelisib (Primary)
Indications Anaplastic large cell lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
Focus Registrational; Therapeutic Use
Acronyms PRIMO
Sponsors Secura Bio; Verastem Oncology

Most Recent Events

07 Dec 2025 Results presented at Secura Bio media release.
07 Dec 2025 According to Secura Bio media release, data from this trial was presented at at the 2025 American Society of Hematology (ASH) Annual Meeting.
04 Nov 2025 According to Secura Bio media release, data from the trial will be presented at the upcoming 2025 American Society of Hematology (ASH) Annual Meeting taking place on December 6-9, 2025 in Orlando, Florida.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com